In a report released today, Jason Mills from Canaccord Genuity reiterated a Buy rating on Cryolife (NYSE: CRY), with a price target of $36. The company’s shares opened today at $32.65, close to its 52-week high of $33.45.
According to TipRanks.com, Mills is a top 25 analyst with an average return of 31.2% and a 74.9% success rate. Mills covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Boston Scientific Corp, and Staar Surgical Company.
Cryolife has an analyst consensus of Moderate Buy, with a price target consensus of $34, representing a 4.1% upside. In a report released today, Northland Securities also maintained a Buy rating on the stock with a $32 price target.
.
See today’s analyst top recommended stocks >>
Based on Cryolife’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $226K. In comparison, last year the company had a net profit of $3.1 million.
Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. Last month, Davis John E, the SVP, Global Sales of CRY sold 3,391 shares for a total of $105,121.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.
